PROCESSA PHARMACEUTICALS INC (PCSA) Stock Price & Overview
NASDAQ:PCSA • US74275C4033
The current stock price of PCSA is 2.88 USD. Today PCSA is down by -1.37%. In the past month the price increased by 23.61%. In the past year, price decreased by -74.21%.
PCSA Key Statistics
- Market Cap
- 6.538M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -34.00
- Dividend Yield
- N/A
PCSA Stock Performance
PCSA Stock Chart
PCSA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PCSA. When comparing the yearly performance of all stocks, PCSA is a bad performer in the overall market: 97.48% of all stocks are doing better.
PCSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PCSA. PCSA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PCSA Earnings
PCSA Forecast & Estimates
7 analysts have analysed PCSA and the average price target is 25.5 USD. This implies a price increase of 785.42% is expected in the next year compared to the current price of 2.88.
PCSA Groups
Sector & Classification
PCSA Financial Highlights
Over the last trailing twelve months PCSA reported a non-GAAP Earnings per Share(EPS) of -34. The EPS increased by 71.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -170.52% | ||
| ROE | -221.71% | ||
| Debt/Equity | 0 |
PCSA Ownership
PCSA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.6 | 943.209B | ||
| JNJ | JOHNSON & JOHNSON | 20.86 | 585.582B | ||
| MRK | MERCK & CO. INC. | 22.45 | 287.316B | ||
| PFE | PFIZER INC | 9.14 | 155.235B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.47 | 122.147B | ||
| ZTS | ZOETIS INC | 16.92 | 50.567B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.04 | 26.934B | ||
| VTRS | VIATRIS INC | 5.57 | 16.085B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.29 | 11.659B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.158B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.518B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.968B | ||
| LGND | LIGAND PHARMACEUTICALS | 26.06 | 4.412B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PCSA
Company Profile
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. The company is headquartered in Vero Beach, Florida and currently employs 10 full-time employees. The company went IPO on 2013-10-07. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
Company Info
IPO: 2013-10-07
PROCESSA PHARMACEUTICALS INC
601 21St Street, Suite 300
Vero Beach FLORIDA 21076 US
CEO: David Young
Employees: 10
Phone: 14437763133
PROCESSA PHARMACEUTICALS INC / PCSA FAQ
What does PCSA do?
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. The company is headquartered in Vero Beach, Florida and currently employs 10 full-time employees. The company went IPO on 2013-10-07. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
Can you provide the latest stock price for PROCESSA PHARMACEUTICALS INC?
The current stock price of PCSA is 2.88 USD. The price decreased by -1.37% in the last trading session.
Does PROCESSA PHARMACEUTICALS INC pay dividends?
PCSA does not pay a dividend.
What is the ChartMill rating of PROCESSA PHARMACEUTICALS INC stock?
PCSA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is PROCESSA PHARMACEUTICALS INC (PCSA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PCSA.
Can you provide the market cap for PROCESSA PHARMACEUTICALS INC?
PROCESSA PHARMACEUTICALS INC (PCSA) has a market capitalization of 6.54M USD. This makes PCSA a Nano Cap stock.
Can you provide the short interest for PCSA stock?
The outstanding short interest for PROCESSA PHARMACEUTICALS INC (PCSA) is 0.51% of its float.